# EDGAR Filing Document

**Accession Number:** 0001870875
**File Stem:** 0000950170-25-083413
**Filing Date:** 2025-6
**Character Count:** 9947
**Document Hash:** 55e4c1fdcf419fc724e47f1acd5a9584
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-083413.hdr.sgml**: 20250606

**ACCESSION NUMBER**: 0000950170-25-083413

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250604

**FILED AS OF DATE**: 20250606

**DATE AS OF CHANGE**: 20250606

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Encrantz Staffan
- **CENTRAL INDEX KEY:** 0001870875

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40587
- **FILM NUMBER:** 251032661

**MAIL ADDRESS:**
- **STREET 1:** C/O SIGHT SCIENCES, INC.
- **STREET 2:** 4040 CAMPBELL AVENUE, SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sight Sciences, Inc.
- **CENTRAL INDEX KEY:** 0001531177
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 800625749
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 4040 CAMPBELL AVE,
- **STREET 2:** SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** (415) 889-0550

**MAIL ADDRESS:**
- **STREET 1:** 4040 CAMPBELL AVE,
- **STREET 2:** SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Encrantz Staffan<br><sub>(Last) (First) (Middle)</sub><br>C/O SIGHT SCIENCES, INC.<br>4040 CAMPBELL AVE., SUITE 100<br><sub>(Street)</sub><br>MENLO PARK, CA 94025<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Sight Sciences, Inc. [ SGHT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-06-04 |  | P |  | 21674 | A | 4.172<sup>(1)</sup> | 1278161 | D |  |
| Common Stock | 2025-06-05 |  | P |  | 40951 | A | 4.244<sup>(2)</sup> | 1319112 | D |  |
| Common Stock | 2025-06-05 |  | A |  | 30952<sup>(3)</sup> | A | $0 | 1350064 | D |  |
| Common Stock | 2025-06-06 |  | P |  | 27900 | A | 4.22<sup>(4)</sup> | 1377964<sup>(5)</sup> | D |  |
| Common Stock |  |  |  |  |  |  |  | 632456 | I | See footnote<sup>(6)</sup> |
| Common Stock |  |  |  |  |  |  |  | 5086920 | I | See footnote<sup>(7)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $4.067 to $4.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(2) The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $4.19 to $4.295 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(3) Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of Common Stock. The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.

(4) The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $4.20 to $4.245 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

(5) Includes (i) 1,347,012 shares of Common Stock, and (ii) 30,952 restricted stock units which are subject to vesting as reported herein.

(6) These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 under the Exchange Act or for any other purpose), except to the extent of his pecuniary interest therein, if any.

(7) These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Exchange Act. However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, these shares are being reported in this report voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose.

**Signature:** /s/ Jeremy Hayden, Attorney-in-Fact for Staffan Encrantz  
**Date:** 2025-06-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**